Dikla Czaczkes Akselbrad stands prominently in the world of life sciences and infection prevention, serving as the CEO of PolyPid. She assumed the reins as executive vice president and chief financial officer in 2017, before navigating the company through its Nasdaq IPO in June 2020. With a repertoire spanning over two decades, Akselbrad has leavened her role with a strategic and financial compass, pioneering financial transitions and raising over $350 million in her previous positions.
Prior to her influential tenure at PolyPid, which began in 2014, Akselbrad held various commanding positions. She functioned as the chief financial officer of both Compugen Ltd and Packet Technologies Ltd. Earlier in her career, she honed her audit and financial proficiency as an audit manager at Ernst & Young Israel, laying a strong foundation for her future endeavors.
Demonstrating an academic commitment to her field, Akselbrad is a distinguished alumnus of Tel-Aviv University, from where she earned her BA in accounting and economics, as well as an MBA. She is also recognized as a certified public accountant in Israel.
In the crucial discourse of surgical infection prevention, surgical site infections (SSIs) have emerged as a growing concern. Traditional systemic antibiotics, according to infection prevention experts, are proving ineffective in curbing this surge. Akselbrad points to localized drug delivery as a potentially promising remedy to this issue. It represents an innovative front in mitigating surgical infections; its targeted approach, compared to systemic antibiotics, might well be the answer to the increasing SSIs.
PolyPid, under Akselbrad’s transformative leadership, is poised to initiate critical advancements in localized drug delivery techniques. Their work may herald a new era in infection prevention, specifically concerning surgical site infections.
Addressing this complicated issue requires innovative thinking, advanced technological adaptations, and dedicated leadership. With Akselbrad at the helm, PolyPid is well-positioned to spearhead these significant evolutions in healthcare.
Source: https://www.infectioncontroltoday.com/authors/dikla-czaczkes-akselbrad-mba